Trial Profile
A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2020
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Drug-induced dyskinesia
- Focus Registrational; Therapeutic Use
- Sponsors Zambon SpA
- 15 Jun 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Mar 2020 According to a Newron Pharmaceuticals media release, the company held discussions with the FDA on the design of this study.
- 12 Sep 2019 According to a Newron Pharmaceuticals media release, the company expected to start this trial in H2 2019.